<DOC>
	<DOCNO>NCT02883049</DOCNO>
	<brief_summary>This randomized phase III trial study well combination chemotherapy work treat young patient newly diagnose B acute lymphoblastic leukemia likely come back spread , patient Philadelphia chromosome ( Ph ) -like tyrosine kinase inhibitor ( TKI ) sensitive mutation . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving one drug ( combination chemotherapy ) give drug different dos different combination may kill cancer cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia Ph-Like TKI Sensitive Mutations</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine administration post-Induction age-adjusted intrathecal triple therapy ( ITT ) Modified Berlin-Frankfurt-Munster ( MBFM ) interim maintenance high-dose methotrexate ( IMHDM ) backbone improve 5-year disease-free survival ( DFS ) child high-risk ( HR ) B-acute lymphoblastic leukemia ( ALL ) compare age-adjusted intrathecal ( IT ) methotrexate ( MTX ) . II . To determine , randomized fashion , cyclophosphamide + etoposide contain regimen ( Experimental Arm 1 ) improve 4-year DFS child , adolescent , young adult high-risk ( VHR ) B-ALL compare modify MBFM-IMHDM regimen contain second IM ( Control Arm ) . SECONDARY OBJECTIVES : I . To determine toxicity tolerability post-Induction age-adjusted ITT compare age-adjusted IT MTX child HR B-ALL . II . To determine toxicity tolerability Experimental Arm 1 compare Control Arm child , adolescent , young adult VHR B-ALL . III . To determine whether single-arm , modify Induction limit anthracycline exposure post-Induction therapy regimen MBFM-IMIDM reduce vincristine ( vincristine sulfate ) /steroid pulse frequency enhance supportive care child Down syndrome ( DS ) HR B-ALL result &gt; = 65 % 5-year DFS &lt; 10 % Induction mortality . IV . To describe outcome child young adult Ph-like B-ALL predict TKI-sensitive mutation treat dasatinib plus MBFM-IMHDM . V. To determine toxicity tolerability MBFM-IMIDM child DS HR B-ALL . VI . To estimate overall survival ( OS ) rate overall regimen ) HR B-ALL b ) VHR B-ALL patient . VII . To determine incidence osteonecrosis ( ON ) , define magnetic resonance ( MR ) imaging , characterize natural history clinically silent ON child , adolescent , young adult 10 year age great assess role drug ( i.e. , asparaginase methotrexate ) addition corticosteroid , risk development ON . VIII . To determine prevalence cognitive deficit measure CogState , child ( age 6 11 year ) HR- VHR B-ALL 1 year therapy , significantly higher normative population ( &gt; 14 % ) follow domain : work memory , executive function , visual motor , process speed , visual attention . TERTIARY OBJECTIVES : I . To determine reduction minimal residual disease ( MRD ) end-Induction end-Consolidation great child , adolescent , young adult VHR B-ALL receive Experimental Arm 1 compare Control Arm . OUTLINE : INDUCTION THERAPY : Patients without Down syndrome receive induction chemotherapy comprise cytarabine intrathecally ( IT ) day 1 ; vincristine sulfate intravenously ( IV ) 1 minute day 1 , 8 , 15 , 22 ; daunorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 , 22 ; dexamethasone orally ( PO ) IV twice daily ( BID ) day 1-14 ( patient 10 year old ) prednisone PO IV BID day 1-28 ( patient least 10 year old ) ; pegaspargase IV 1-2 hour day 4 ; methotrexate IT day 8 29 CNS1 CNS2 ( plus day 15 22 CNS3 patient ) . Treatment continue 56 day absence disease progression unacceptable toxicity . CONSOLIDATION THERAPY : Patients randomize 1 2 treatment arm . ARM I HR B-ALL CONSOLIDATION ( C ) : Patients receive consolidation therapy comprise cyclophosphamide IV 30-60 minute day 1 29 ; cytarabine IV 1-30 minute subcutaneously ( SC ) day 1-4 , 8-11 , 29-32 , 36-39 ; mercaptopurine PO daily ( QD ) day 1-14 29-42 , methotrexate IT day 1 , 8 , 15 , 22 ; vincristine sulfate IV 1 minute day 15 , 22 , 43 , 50 ; pegaspargase IV 1-2 hour day 15 43 . Patients continue clinical evidence testicular leukemia undergo radiotherapy ( RT ) QD , 5 day week , approximately 2½ week ( 12 fraction total ) . Treatment continue 56 day absence disease progression unacceptable toxicity . ARM II HR B-ALL C : Patients receive Consolidation therapy Arm I HR B-ALL C. Patients also receive ITT comprise methotrexate , hydrocortisone sodium succinate , cytarabine day 1 , 8 , 15 , 22 . Patients testicular leukemia also undergo RT Arm I HR B-ALL C. INTERIM MAINTENANCE THERAPY : ARM I HR B-ALL INTERIM MAINTENANCE ( IM ) : Patients receive IM therapy comprise vincristine sulfate IV 1 minute day 1 , 15 , 29 , 43 ; high-dose methotrexate IV 24 hour day 1 , 15 , 29 , 43 ; leucovorin calcium PO IV day 3-4 , 17-18 , 31-32 , 45-46 ; methotrexate IT day 1 29 ; mercaptopurine PO day 1-56 . Treatment continue 63 day absence disease progression unacceptable toxicity . ARM II HR B-ALL IM : Patients receive ITT day 1 29 IM therapy Arm I HR-ALL IM . Treatment continue 63 day absence disease progression unacceptable toxicity . DELAYED INTENSIFICATION THERAPY : ARM I HR B-ALL DELAYED INTENSIFICATION ( DI ) : Patients receive DI therapy comprise vincristine sulfate IV 1 hour day 1 , 8 , 15 , 43 , 50 ; dexamethasone PO IV BID day 1-7 15-21 ; doxorubicin hydrochloride IV 1-60 minute day 1 , 8 , 15 ; methotrexate IT day 1 , 29 , 36 ; pegaspargase IV 1-2 hour day 4 43 ; cyclophosphamide IV 30-60 minute day 29 ; cytarabine IV 1-30 minute SC day 29-32 36-39 ; thioguanine PO QD day 29-42 . Treatment continue 56 day absence disease progression unacceptable toxicity . ARM II HR B-ALL DI : Patients receive ITT day 1 , 29 , 36 DI therapy Arm I HR B-ALL DI . MAINTENANCE ( M ) THERAPY : ARM I HR B-ALL M : Patients receive maintenance therapy comprise vincristine sulfate IV 1 minute day 1 , 29 , 57 ; methotrexate IT day 1 ( also day 29 course 1-4 ) ; prednisone PO BID day 1-5 , 29-33 ( may receive methylprednisolone IV PO tolerate ) , 57-61 ; mercaptopurine PO QD day 1-84 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . Treatment repeat every 12 week 2 year ( female ) 3 year ( male ) absence disease progression unacceptable toxicity . ARM II HR B-ALL M : Patients receive ITT day 1 ( also day 29 course 1-4 ) maintenance therapy Arm I HR B-ALL M. Treatment repeat every 12 week 2 year ( female ) 3 year ( male ) absence disease progression unacceptable toxicity . VERY HIGH-RISK B-ALL : Patients randomize 1 3 treatment arm . CONSOLIDATION THERAPY PART I : In arm , patient receive cyclophosphamide IV 30-60 minute day 1 ; cytarabine IV SC day 1-4 8-11 ; mercaptopurine PO QD day 1-14 ; methotrexate IT day 1 , 8 , 15 , 22 ( day 1 8 CNS3 patient ) ; vincristine sulfate IV 1 minute day 15 22 ; pegaspargase IV 1-2 hour day 15 . Patients continue clinical evidence testicular leukemia undergo RT QD , 5 day week , approximately 2½ week ( 12 fraction total ) . Treatment continue 28 day absence disease progression unacceptable toxicity . CONSOLIDATION THERAPY PART II : ARM A VHR B-ALL C ( CONTROL ARM ) : Patients receive consolidation therapy comprise cyclophosphamide IV 30-60 minute day 29 ; cytarabine IV 1-30 minute SC day 29-32 36-39 ; mercaptopurine PO QD day 29-42 ; vincristine sulfate IV 1 minute day 43 50 ; pegaspargase IV 1-2 hour day 43 . Treatment continue 28 day absence disease progression unacceptable toxicity . ARM B VHR B-ALL C ( EXPERIMENTAL ARM ) : Patients receive consolidation therapy comprise cyclophosphamide IV 15-30 minute day 29-33 ; etoposide IV 60-120 minute day 29-33 ; vincristine sulfate IV 1 minute day 43 50 ; pegaspargase IV 1-2 hour day 43 . Treatment continue 28 day absence disease progression unacceptable toxicity . ARM C VHR B-ALL C : Patients receive clofarabine IV 2 hour day 29-33 consolidation therapy Arm B VHR B-ALL C. ( Closed 9/12/2014 ) INTERIM MAINTENANCE I : In arm , patient receive vincristine sulfate IV 1 minute day 1 , 15 , 29 , 43 ; high-dose methotrexate IV 24 hour day 1 , 15 , 29 , 43 ; leucovorin calcium PO IV day 3-4 , 17-18 , 31-32 , 45-46 ; mercaptopurine PO QD day 1-56 ; methotrexate IT day 1 29 . Treatment continue 63 day absence disease progression unacceptable toxicity . DELAYED INTENSIFICATION PART I : In arm , patient receive vincristine sulfate IV 1 minute day 1 , 8 , 15 ; dexamethasone PO IV BID day 1-7 15-21 ; doxorubicin hydrochloride IV 1-60 minute day 1 , 8 , 15 ; methotrexate IT day 1 ; pegaspargase IV 1-2 hour day 4 . Treatment continue 28 day absence disease progression unacceptable toxicity . DELAYED INTENSIFICATION PART II : ARM A VHR B-ALL DI ( CONTROL ARM ) : Patients receive DI therapy comprise cyclophosphamide IV 30-60 minute day 29 ; cytarabine IV 15-30 minute SC day 29-32 36-39 ; thioguanine PO QD day 29-42 ; methotrexate IT day 29 36 ; vincristine sulfate IV 1 minute day 43 50 ; pegaspargase IV 1-2 hour day 43 . Treatment continue 28 day absence disease progression unacceptable toxicity . ARM B VHR B-ALL DI ( EXPERIMENTAL ARM ) : Patients receive DI therapy comprise cyclophosphamide IV 15-30 minute day 29-33 ; etoposide IV 60-120 minute day 29-33 ; methotrexate IT day 29 36 ; vincristine sulfate IV 1 minute day 43 50 ; pegaspargase IV 1-2 hour day 43 . Treatment continue 28 day absence disease progression unacceptable toxicity . ARM C VHR B-ALL DI : Patients receive clofarabine IV 2 hour day 29-33 DI therapy Arm II B VHR B-ALL DI . ( Closed 9/12/2014 ) INTERIM MAINTENANCE II : In arm , patient receive vincristine sulfate IV 1 minute methotrexate IV 2-5 minute ( undiluted ) 10-15 minute ( dilute ) day 1 , 11 , 21 , 31 , 41 ; pegaspargase IV 1-2 hour day 2 22 ; methotrexate IT day 1 31 . Treatment continue 56 day absence disease progression unacceptable toxicity . MAINENTANCE THERAPY : Patients CNS3 disease diagnosis undergo RT QD 4 week ( 10 fraction total ) . In arm , patient receive vincristine sulfate IV 1 minute day 1 , 29 , 57 ; prednisone PO BID day 1-5 , 29-33 , 57-61 ( may receive methylprednisolone IV PO tolerate ) ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ( except methotrexate IT day ) ; mercaptopurine PO QD day 1-84 ; methotrexate IT day 1 ( also day 29 course 1 2 CNS patient undergo RT ) . Treatment repeat every 12 week 2 year ( female ) 3 year ( male ) absence disease progression unacceptable toxicity . INDUCTION THERAPY : All patient receive cytarabine IT day 1 ; vincristine sulfate IV 1 minute day 1 8 , dexamethasone PO IV BID ( patient 10 year old ) prednisone PO BID ( patient least 10 year old ) day 1-14 ( may receive methylprednisolone IV PO tolerate ) , pegaspargase IV 1-2 hour day 4 ; methotrexate IT day 8 ; leucovorin calcium PO day 10-11 . Treatment continue 14 day absence disease progression unacceptable toxicity . Rapid early responder ( RER ) : Patients receive induction therapy comprise vincristine sulfate IV 1 minute day 15 22 ; dexamethasone PO BID prednisone PO BID day 15-28 ; methotrexate IT day 29 ( also day 15 22 CNS3 patient ) ; leucovorin calcium PO day 31-32 ( also day 17-18 24-25 CNS3 patient ) . Treatment continue 14 day absence disease progression unacceptable toxicity . Slow early responder ( SER ) : Patients receive daunorubicin hydrochloride IV 1-15 minute day 15 Induction therapy RER patient . Treatment continue 14 day absence disease progression unacceptable toxicity . CONSOLIDATION THERAPY : All patient receive cyclophosphamide IV 30-60 minute day 1 29 ; cytarabine IV 1-30 minute SC day 1-4 , 8-11 , 29-32 , 36-39 ; mercaptopurine PO QD day 1-14 29-42 ; vincristine sulfate IV 1 minute day 15 , 22 , 43 , 50 ; pegaspargase IV 1-2 hour day 15 43 ; methotrexate IT day 1 , 8 , 15 , 22 ( day 1 8 CNS3 patient ) ; leucovorin calcium PO day 3-4 , 10-11 , 17-18 , 24-25 . Patients continue clinical evidence testicular leukemia undergo RT QD , 5 day week , approximately 2½ week ( 12 fraction total ) . Treatment continue 56 day absence disease progression unacceptable toxicity . INTERIM MAINTENANCE THERAPY : Patients receive vincristine sulfate IV 1 minute day 1 , 15 , 29 , 43 ; intermediate dose methotrexate IV 24 hour day 1 , 15 , 29 , 43 ; leucovorin calcium PO IV day 2-3 , 17-18 , 31-32 , 45-46 ; mercaptopurine PO QD day 1-56 ; methotrexate IT day 1 29 . Treatment continue 63 day absence disease progression unacceptable toxicity . DELAYED INTENSIFICATION THERAPY : Patients receive vincristine sulfate IV 1 minute day 1 , 8 , 15 , 43 , 50 ; dexamethasone PO BID IV day 1-7 15-21 ; doxorubicin hydrochloride IV 1-60 minute day 1 , 8 , 15 ; pegaspargase IV 1-2 hour day 4 43 ; cyclophosphamide IV 30-60 minute day 29 ; thioguanine PO QD day 29-42 ; cytarabine IV 1-30 minute SC day 29-32 36-39 ; methotrexate IT day 1 , 29 , 36 ; leucovorin calcium PO day 3-4 , 31-32 38-39 . MAINTENANCE THERAPY : Patients CNS3 disease undergo RT QD , 5 day week , 2 week ( 10 fraction total ) . Patients receive vincristine sulfate IV 1 minute day 1 ; prednisone PO BID IV day 1-5 ( may receive methylprednisolone IV PO tolerate ) ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; mercaptopurine PO QD day 1-84 ; methotrexate IT day 1 ( also day 29 course 1-4 CNS3 patient undergo RT ) . Treatment repeat every 12 week 2 year absence disease progression unacceptable toxicity . PH-LIKE PREDICTED TKI-SENSITIVE KINASE MUTATION : CONSOLIDATION THERAPY : Patients receive dasatinib PO QD day 1-56 , cyclophosphamide IV 30-60 minute day 1 29 , cytarabine IV 1-30 minute SC day 1-4 , 8-11 , 29-32 36-39 , mercaptopurine PO day 1-14 29-42 , methotrexate IT day 1 , 8 , 15 22 , vincristine sulfate IV 1 minute day 15 , 22 , 43 50 , pegaspargase IV 1-2 hour day 15 43 . INTERIM MAINTENANCE THERAPY : Patients receive dasatinib PO QD day 1-63 , vincristine sulfate IV 1 minute day 1 , 15 , 29 , 43 , high dose methotrexate IV 24 hour day 1 , 15 , 29 , 43 , leucovorin calcium PO IV day 3-4 , 17-18 , 31-32 , 45-46 , methotrexate IT day 1 29 , mercaptopurine PO day 1-56 . DELAYED INTENSIFICATION THERAPY : Patients receive dasatinib PO QD day 1-56 , vincristine sulfate IV 1 minute day 1 , 8 , 15 , 43 , 50 , dexamethasone PO IV day 1-7 15-21 , doxorubicin hydrochloride IV 1-15 minute day 1 , 8 15 , methotrexate IT day 1 , 29 36 , pegaspargase IV 1-2 hour day 4 43 , cyclophosphamide IV 30-60 minute day 29 , cytarabine IV 1-30 minute SC day 29-32 36-39 , thioguanine PO day 29-42 . INTERIM MAINTENANCE THERAPY II : Patients dasatinib PO QD day 1-56 , vincristine sulfate IV 1 minute day 1 , 11 , 21 , 31 , 41 , methotrexate IV 15 minute day 1 , 11 , 21 , 31 41 , methotrexate IT day 1 31 , pegaspargase IV 1-2 hour day 2 22 . MAINTENANCE THERAPY : Patients receive dasatinib PO QD day 1-84 , vincristine sulfate IV 1 minute day 1 , 29 57 , prednisone PO BID IV day 1-5 , 29-33 57-61 , methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 78 ( omit day MTX [ IT ] give ) , mercaptopurine PO day 1-84 , methotrexate IT day 1 ( also day 29 course 1 2 , patient receive CNS radiation ) . Treatment repeat every 12 week 2 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Patients must enrol AALL08B1 prior enrollment AALL1131 White Blood Cell Count ( WBC ) Criteria Age 19.99 year : WBC &gt; = 50 000/uL Age 1030.99 year : Any WBC Age 130.99 year : Any WBC : Testicular leukemia CNS leukemia ( CNS3 ) Steroid pretreatment Patients must newly diagnose B lymphoblastic leukemia ( 2008 World Health Organization [ WHO ] classification ) ( also term Bprecursor acute lymphoblastic leukemia ) ; patient Down syndrome also eligible Organ function requirement patient Phlike ALL predict TKIsensitive mutation patient identify Phlike dasatinibsensitive kinase mutation must assessment organ function perform within 3 day study entry eligible dasatinib arm AALL1131 Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; 70mL/min/1.73 m^2 serum creatinine base age/gender follow : Age : Maximum Serum Creatinine ( mg/dL ) 1 &lt; 6 month : 0.4 ( male ) 0.4 ( female ) 6 month &lt; 1 year : 0.5 ( male ) 0.5 ( female ) 1 &lt; 2 year : 0.6 ( male ) 0.6 ( female ) 2 &lt; 6 year : 0.8 ( male ) 0.8 ( female ) 6 &lt; 10 year : 1.0 ( male ) 1.0 ( female ) 10 &lt; 13 year : 1.2 ( male ) 1.2 ( female ) 13 &lt; 16 year : 1.5 ( male ) 1.4 ( female ) &gt; 16 year : 1.7 ( male ) 1.4 ( female ) Direct bilirubin = &lt; 3 x upper limit normal ( ULN ) age , Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 10 x upper limit normal ( ULN ) age Shortening fraction &gt; = 27 % echocardiogram , ejection fraction &gt; = 50 % gate radionuclide study Patients must electrocardiogram ( EKG ) few 6 day prior enrollment dasatinib arm ; patient cardiac assessment echocardiogram radionuclide scan begin induction need repeat prior study entry ; correct QT interval ( QTc ) &lt; 450 msec baseline electrocardiogram measure Frederica Bazett formula No major conduction abnormality ( unless cardiac pacemaker present ) No evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % sea level clinical indication determination Patients seizure disorder may enrol anticonvulsant well control ; however , drug induce CYP3A4/5 ( carbamazepine , oxcarbazepine , phenytoin , primidone , phenobarbital ) avoid Eligibility criterion Incidence Natural History Osteonecrosis study Patients must 10 year age great time BALL diagnosis , enrol AALL1131 Patients Down syndrome Phlike predict TKIsensitive mutation eligible Eligibility criterion Longitudinal , Computerized Assessment Neurocognitive Functioning study Patients must age 6 11 year time BALL diagnosis , enrol AALL1131 Patients must English , French Spanishspeaking ( languages assessment available ) Patients must know history neurodevelopmental disorder prior diagnosis BALL ( e.g. , Down syndrome , Fragile X , William 's Syndrome , mental retardation ) Patients must significant visual impairment would prevent computer use recognition visual test stimulus Eligibility criteria National Cancer Institute ( NCI ) standard risk patient AALL0932 enrol study end Induction Patients enrol AALL0932 , without Down syndrome , meet follow criterion NOT eligible continue AALL0932 WILL BE eligible enroll HR BALL stratum study end Induction : Without favorable cytogenetics ( ETV6RUNX1 double trisomy 4+10 ) , day 8 peripheral blood ( PB ) minimal residual disease ( MRD ) &gt; = 1 % day 29 BM MRD &lt; 0.01 % With favorable cytogenetics ( ETV6RUNX1 double trisomy 4+10 ) , day 8 PB MRD day 29 bone marrow ( BM ) MRD &gt; = 0.01 % Both NCI standard risk ( SR ) HR patient without Down syndrome testicular disease diagnosis , meet VHR criterion , eligible HR stratum Patients enrol AALL0932 , without Down syndrome , meet follow criterion NOT eligible continue AALL0932 WILL BE eligible enroll VHR BALL stratum study end Induction : Intrachromosomal amplification chromosome 21 ( iAMP21 ) Mixedlineage leukemia ( MLL ) rearrangement Hypodiploidy ( n &lt; 44 chromosome and/or deoxyribonucleic acid [ DNA ] index &lt; 0.81 ) Induction failure ( M3 BM day 29 ) Without favorable cytogenetics ( ETV6RUNX1 double trisomy 4+10 ) , day 29 BM MRD &gt; = 0.01 % Patients enrol AALL0932 , Down syndrome , meet follow criterion NOT eligible continue AALL0932 WILL BE eligible enroll DS HR BALL stratum study end Induction : Day 29 MRD &gt; = 0.01 % MLL rearrangement Hypodiploidy ( n &lt; 45 chromosome and/or DNA index &lt; 0.81 ) DS HR BALL patient initially enrol AALL0932 study Induction failure ( M3 BM day 29 ) Philadelphia chromosome ( BCRABL1 ) eligible postInduction therapy either trial ( AALL0932 AALL1131 ) All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , NCI requirement human study must meet With exception steroid pretreatment administration intrathecal cytarabine , patient must receive prior cytotoxic chemotherapy either current diagnosis BALL cancer diagnose prior initiation protocol therapy AALL1131 ; patient secondary BALL develop treatment prior malignancy cytotoxic chemotherapy ; patient receive prior steroid therapy may eligible AALL1131 Patients BCRABL1 fusion eligible postinduction therapy study may eligible enroll successor Children 's Oncology Group ( COG ) Philadelphia positive ( Ph+ ) ALL trial day 15 Induction DS HR BALL patient Induction failure BCRABL1 Female patient pregnant ineligible Lactating female eligible unless agree breastfeed infant Female patient childbearing potential eligible unless negative pregnancy test result obtain Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration study participation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>